Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kenneth Carl Anderson, M.D.

Co-Author

This page shows the publications co-authored by Kenneth Anderson and Andrew Yee.
Connection Strength

0.665
  1. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014 Aug; 166(3):401-9.
    View in: PubMed
    Score: 0.144
  2. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer. 2022 Feb 15.
    View in: PubMed
    Score: 0.062
  3. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022 Feb; 9(2):e143-e161.
    View in: PubMed
    Score: 0.062
  4. Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. Leukemia. 2022 Apr; 36(4):1078-1087.
    View in: PubMed
    Score: 0.061
  5. Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. Nat Cell Biol. 2021 11; 23(11):1199-1211.
    View in: PubMed
    Score: 0.060
  6. Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma. Clin Cancer Res. 2021 12 01; 27(23):6432-6444.
    View in: PubMed
    Score: 0.060
  7. A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2019 01 15; 25(2):478-486.
    View in: PubMed
    Score: 0.049
  8. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 07; 182(2):222-230.
    View in: PubMed
    Score: 0.047
  9. Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018 08; 32(8):1838-1841.
    View in: PubMed
    Score: 0.047
  10. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma. Mol Cancer Ther. 2014 Nov; 13(11):2489-500.
    View in: PubMed
    Score: 0.037
  11. Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res. 2014 Aug 01; 20(15):3955-61.
    View in: PubMed
    Score: 0.036
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.